Magnesium-based interventions for normal kidney function and chronic kidney disease

Magnesium Research

Volumn 29, Issue 4, 2016, Pages 126-140

  Massy, Ziad A ^a,b   Nistor, Ionut ^c,d   Apetrii, Mugurel ^c   Brandenburg, Vincent M ^e   Bover, Jordi ^f   Evenepoel, Pieter ^g   Goldsmith, David ^h   Mazzaferro, Sandro ⁱ   Urena Torres, Pablo ^j   Vervloet, Marc G ^k   Cozzolino, Mario ^l   Covic, Adrian ^c  

^a HÔPITAL AMBROISE PARÉ   (France)

^b CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^c GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^f FUNDACIÓ PUIGVERT   (Spain)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j HÔPITAL NECKER ENFANTS MALADES   (France)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

Cardiovascular; CKD; Magnesium; Mortality

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CALCINEURIN INHIBITOR; CALCIUM ACETATE; CALCIUM CARBONATE; CISPLATIN; FIBROBLAST GROWTH FACTOR 23; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM; MAGNESIUM CARBONATE; MATRIX GLA PROTEIN; MEMBRANE PROTEIN; PARATHYROID HORMONE; PHOSPHATE; PROTON PUMP INHIBITOR; SEVELAMER; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

ARTERIAL WALL THICKNESS; ATRIAL FIBRILLATION; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY FAILURE; CONCENTRATION (PARAMETERS); HEMODIALYSIS; HUMAN; HYPERMAGNESEMIA; HYPOMAGNESEMIA; KIDNEY FUNCTION; META ANALYSIS (TOPIC); MINERAL SUPPLEMENTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; DRUG EFFECTS; KIDNEY; METABOLISM; RENAL INSUFFICIENCY, CHRONIC;

ANIMALS; HUMANS; KIDNEY; MAGNESIUM; RENAL INSUFFICIENCY, CHRONIC;

EID: 85011635868     PISSN: 09531424     EISSN: 19524021     Source Type: Journal    
DOI: 10.1684/mrh.2016.0412     Document Type: Review

References (86)

1. Maguire ME, Cowan JA. Magnesium chemistry and biochemistry. Biometals 2002; 15: 203-10.
2. Fox C, Ramsoomair D, Carter C. Magnesium: its proven and potential clinical significance. South Med J 2001; 94: 1195-201.
3. Lewellen TK, Nelp WB, Murano R, Hinn GM, Chesnut 3rd CH. Absolute measurement of total-body calcium by the Ar-37 method-preliminary results: concise communication. J Nucl Med 1977; 18: 929-32.
4. Elin RJ. Assessment of magnesium status for diagnosis and therapy. Magnes Res 2010; 23: S194-8.
5. Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin Kidney J 2012; 5: i3-14.
6. Bringhurst FRDMKS, Kronenberg HM. Bone and mineral metabolism in health and disease. Harrison’s principles of internal medicine. 18 ed. New York: McGraw-Hill, 2012.
7. Hartwig A. Role of magnesium in genomic stability. Mutat Res 2001; 475: 113-21.
8. Drueke TBLB. Magnesium homeostasis and disorders of magnesium metabolism. In: Feehally JFJ, Johnson RJ, eds. Comprehensive Clin Nephrol. Philadelphia: Mosby, 2007, 136-8.
9. Hashizume N, Mori M. An analysis of hypermagnesemia and hypomagnesemia. Jpn J Med 1990; 29: 368-72.
10. Konrad M, Schlingmann KP. Inherited disorders of renal hypomagnesaemia. Nephrol Dial Transplant 2014; 29: iv63-71.
11. de Baaij JHF, Hoenderop JGJ, Bindels RJM. Regulation of magnesium balance: lessons learned from human genetic disease. Clin Kidney J 2012; 5: i15-24.
12. Kafka H, Langevin L, Armstrong PW. Serum magnesium and potassium in acute myocardial infarction. Influence on ventricular arrhythmias. Arch Intern Med 1987; 147: 465-9.
13. Ceremuzynski L, Gebalska J, Wolk R, Makowska E. Hypomagnesemia in heart failure with ventricular arrhythmias. Beneficial effects of magnesium supplementation. J Intern Med 2000; 247: 78-86.
14. Rubeiz GJ, Thill-Baharozian M, Hardie D, Carlson RW. Association of hypomagnesemia and mortality in acutely ill medical patients. Crit Care Med 1993; 21: 203-9.
15. Touyz RM. Magnesium in clinical medicine. Front Biosci 2004; 9: 1278-93.
16. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-429.
17. Miller S, Crystal E, Garfinkle M, Lau C, Lashevsky I, Connolly SJ. Effects of magnesium on atrial fibrillation after cardiac surgery: a meta-analysis. Heart 2005; 91: 618-23.
18. Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992; 339: 1553-8.
19. ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345: 669-85.
20. Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. Lancet 2002; 360: 1189-96.
21. Steg PG, James S K, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-619.
22. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e385-484.
23. Jee SH, Miller 3rd ER, Guallar E, et al. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. Am J Hypertens 2002; 15: 691-6.
24. Dickinson HO, Nicolson DJ, Campbell F, et al. Magnesium supplementation for the management of essential hypertension in adults. Cochrane Database Syst Rev 2006; 3: Cd004640.
25. Whang R, Chrysant S, Dillard B, Smith W, Fryer A. Hypomagnesemia and hypokalemia in 1,000 treated ambulatory hypertensive patients. J Am Coll Nutr 1982; 1: 317-22.
26. Salem S, Bruck H, Bahlmann FH, et al. Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol 2012; 35: 31-9.
27. Van Laecke S, Marechal C, Verbeke F, et al. The relation between hypomagnesaemia and vascular stiffness in renal transplant recipients. Nephrol Dial Transplant 2011; 26: 2362-9.
28. Kanbay M, Yilmaz MI, Apetrii M, et al. Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. Am J Nephrol 2012; 36: 228-37.
29. Hruby A, O’Donnell CJ, Jacques PF, Meigs JB, Hoffmann U, McKeown NM. Magnesium intake is inversely associated with coronary artery calcification: the Framingham Heart Study. J Am Coll Cardiol 2014; 7: 59-69.
30. Qu X, Jin F, Hao Y, et al. Magnesium and the risk of cardiovascular events: a meta-analysis of prospective cohort studies. PloS One 2013; 8: e57720.
31. Floege J. Magnesium in CKD: more than a calcification inhibitor? J Nephrol 2014; 28: 269-77.
32. Pham PC, Pham PM, Pham SV, Miller JM, Pham PT. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007; 2: 366-73.
33. Pham PC, Pham PM, Pham PA, et al. Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. Clin Nephrol 2005; 63: 429-36.
34. Dong JY, Xun P, He K, Qin LQ. Magnesium intake and risk of type 2 diabetes: meta-analysis of prospective cohort studies. Diabetes Care 2011; 34: 2116-22.
35. Massry SG. Magnesium homeostasis in patients with renal failure. Contrib Nephrol 1984; 38: 175-84.
36. Norman DA, Fordtran JS, Brinkley LJ, et al. Jejunal and ileal adaptation to alterations in dietary calcium: changes in calcium and magnesium absorption and pathogenetic role of parathyroid hormone and 1,25-dihydroxyvitamin D. J Clin Invest 1981; 67: 1599-603.
37. Cunningham J, Rodríguez M, Messa P. Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients. Clin Kidney J 2012; 5: i39-51.
38. O’Donnell JM, Smith MW. Uptake of calcium and magnesium by rat duodenal mucosa analysed by means of competing metals. J Physiol 1973; 229: 733-49.
39. Hardwick LL, Jones MR, Brautbar N, Lee DB. Magnesium absorption: mechanisms and the influence of vitamin D, calcium and phosphate. J Nutr 1991; 121: 13-23.
40. Pedrozzi NE, Truttmann AC, Faraone R, et al. Circulating ionized and total magnesium in end-stage kidney disease. Nephron 1998; 79: 288-92.
41. Wyskida K, Witkowicz J, Chudek J, Wiecek A. Daily magnesium intake and hypermagnesemia in hemodialysis patients with chronic kidney disease. J Ren Nutr 2012; 22: 19-26.
42. Ferre S, Baldoli E, Leidi M, Maier JA. Magnesium deficiency promotes a pro-atherogenic phenotype in cultured human endothelial cells via activation of NFkB. Biochim Biophys Acta 2010; 1802: 952-8.
43. Van Laecke S, Nagler EV, Verbeke F, Van Biesen W, Vanholder R. Hypomagnesemia and the risk of death and GFR decline in chronic kidney disease. Am J Med 2013; 126: 825-31.
44. Li L, Streja E, Rhee CM, et al. Hypomagnesemia and mortality in incident hemodialysis patients. Am J Kidney Dis 2015; 66: 1047-55.
45. Ma J, Folsom AR, Melnick SL, et al. Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study, Atherosclerosis Risk in Communities Study. J Clin Epidemiol 1995; 48: 927-40.
46. Hashimoto T, Hara A, Ohkubo T, et al. Serum magnesium, ambulatory blood pressure, and carotid artery alteration: the Ohasama study. Am J Hypertens 2010; 23: 1292-8.
47. van den Broek FA, Beynen AC. The influence of dietary phosphorus and magnesium concentrations on the calcium content of heart and kidneys ofDBA/2 and NMRI mice. Lab Anim 1998; 32: 483-91.
48. Schwille PO, Schmiedl A, Schwille R, et al. Media calcification, low erythrocyte magnesium, altered plasma magnesium, and calcium homeostasis following grafting of the thoracic aorta to the infrarenal aorta in the rat – differential preventive effects of long-term oral magnesium supplementation alone and in combination with alkali. Biomed Pharmacother 2003; 57: 88-97.
49. Kircelli F, Peter ME, Sevinc Ok E, et al. Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner. Nephrol Dial Transplant 2012; 27: 514-21.
50. Ishimura E, Okuno S, Yamakawa T, Inaba M, Nishizawa Y. Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res 2007; 20: 237-44.
51. Meema HE, Oreopoulos DG, Rapoport A. Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int 1987; 32: 388-94.
52. Pasch A, Farese S, Graber S, et al. Nanoparticlebased test measures overall propensity for calcification in serum. J Am Soc Nephrol 2012; 23: 1744-52.
53. Vetter T, Lohse MJ. Magnesium and the parathyroid. Current opinion in nephrology and hypertension 2002; 11: 403-10.
54. Kawata T, Nagano N. The calcium receptor and magnesium metabolism. Clin Calcium 2005; 15: 43-50.
55. Rodriguez-Ortiz ME, Canalejo A, Herencia C, et al. Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration. Nephrol Dial Transplant 2014; 29: 282-9.
56. Navarro JF, Mora C, Jimenez A, Torres A, Macia M, Garcia J. Relationship between serum magnesium and parathyroid hormone levels in hemodialysis patients. Am J Kidney Dis 1999; 34: 43-8.
57. Navarro JF, Mora C, Macia M, Garcia J. Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients. Perit Dial Int 1999; 19: 455-61.
58. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 2014; 85: 174-81.
59. Fournier A, Moriniere P, Boudailliez B, et al. Prevention of radiologically obvious hyperparathyroidism in dialyses patients by i.v. 1alphaOH vitamin D3 (Etalpha) in association with Mg(OH)2 as sole phosphate binder. [German] Pravention des radiologisch manifesten hyperparathyreodismus bei dialysepatienten mit intravenosem 1alphaOH vitamin D3 und Mg(OH)2 als alleinigem phosphatbinder. Nierenund Hochdruckkrankheiten 1993; 22: 39-44.
60. Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E. Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int 1996; 49: 163-7.
61. Kyriazis J, Kalogeropoulou K, Bilirakis L, et al. Dialysate magnesium level and blood pressure. Kidney Int 2004; 66: 1221-31.
62. Spiegel DM. The role of magnesium binders in chronic kidney disease. Semin Dial 2007; 20: 333-6.
63. Tzanakis IP, Papadaki AN, Wei M, et al. Magnesium carbonate for phosphate control in patients on hemodialysis.Arandomized controlled trial. Int Urol Nephrol 2008; 40: 193-201.
64. Turgut F, Kanbay M, Metin MR, Uz E, Akcay A, Covic A. Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol 2008; 40: 1075-82.
65. de Francisco AL, Leidig M, Covic AC, et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010; 25: 3707-17.
66. Zwiech R, Dryja P, Acina D, Króliczak V, Chrul S, Kacprzyk F. The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients. Wiad Lek 2011; 64: 9-14.
67. Mortazavi M, Moeinzadeh F, Saadatnia M, Shahidi S, McGee JC, Minagar A. Effect of magnesium supplementation on carotid intima-media thickness and flow-mediated dilatation among hemodialysis patients: a double-blind, randomized, placebo-controlled trial. Eur Neurol 2013; 69: 309-16.
68. Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011; 26: 1948-55.
69. Hutchison AJ, Wilkie M. Use of magnesium as a drug in chronic kidney disease. Clin Kidney J 2012; 5: i62-70.
70. McIntyre CW, Pai P, Warwick G, Wilkie M, Toft AJ, Hutchison AJ. Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 401-9.
71. Nastou D, Fernandez-Fernandez B, Elewa U, et al. Next-generation phosphate binders: focus on ironbased binders. Drugs 2014; 74: 863-77.
72. de Francisco AL, Leidig M, Covic AC, et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010; 25: 3707-17.
73. Covic A, Passlick-Deetjen J, Kroczak M, et al. A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol Dial Transplant 2013; 28: 2383-92.
74. Neven E, De Schutter TM, Dams G, et al. A magnesium based phosphate binder reduces vascular calcification without affecting bone in chronic renal failure rats. PloS One 2014; 9: e107067.
75. Verberckmoes SC, Persy V, Behets GJ, et al. Uremiarelated vascular calcification: more than apatite deposition. Kidney Int 2007; 71: 298-303.
76. Gorgels TG, Waarsing JH, de Wolf A, ten Brink JB, Loves WJ, Bergen AA. Dietary magnesium, not calcium, prevents vascular calcification in a mouse model for pseudoxanthoma elasticum. J Mol Med 2010; 88: 467-75.
77. De Schutter TM, Behets GJ, Geryl H, et al. Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia. Kidney Int 2013; 83: 1109-17.
78. Zyryanov AB, Shestakov AS, Lahti R, Baykov AA. Mechanism by which metal cofactors control substrate specificity in pyrophosphatase. Biochem J 2002; 367: 901-6.
79. Liu F, Zhang X, Qi H, et al. Correlation of serum magnesium with cardiovascular risk factors in maintenance hemodialysis patients – a cross-sectional study. Magnes Res 2013; 26: 100-8.
80. Louvet L, Bazin D, Buchel J, Steppan S, Passlick-Deetjen J, Massy ZA. Characterisation of calcium phosphate crystals on calcified human aortic vascular smooth muscle cells and potential role of magnesium. PloS One 2015; 10: e0115342.
81. Tzanakis I, Pras A, Kounali D, et al. Mitral annular calcifications in haemodialysis patients: a possible protective role of magnesium. Nephrol Dial Transplant 1997; 12: 2036-7.
82. Barbagallo M, Dominguez LJ. Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance. Arch Biochem Biophys 2007; 458: 40-7.
83. Aydin H, Deyneli O, Yavuz D, et al. Short-term oral magnesium supplementation suppresses bone turnover in postmenopausal osteoporotic women. Biol Trace Elem Res 2010; 133: 136-43.
84. Van Laecke S, Nagler EV, Verbeke F, Van Biesen W, Vanholder R. Hypomagnesemia and the risk of death and GFR decline in chronic kidney disease. Am J Med 2013; 126: 825-31.
85. Massy ZA, Drüeke TB. Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. Clin Kidney J 2012; 5: i52-61.
86. Spiegel DM, Farmer B, Smits G, Chonchol M. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. J Ren Nutr 2007; 17: 416-22.